SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

Search

Laboratorios Farmaceuticos Rovi SA

Deschisă

SectorSănătate

51.2 0.99

Rezumat

Modificarea prețului

24h

Curent

Minim

50.15

Maxim

51.45

Indicatori cheie

By Trading Economics

Venit

-57M

32M

Vânzări

199M

434M

P/E

Medie Sector

19.288

63.778

EPS

0.457

Randament dividend

2.11

Marjă de profit

7.411

Angajați

2,197

EBITDA

40M

138M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+43.34% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.11%

2.39%

Următoarele câștiguri

7 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-770M

2.6B

Deschiderea anterioară

50.21

Închiderea anterioară

51.2

Sentimentul știrilor

By Acuity

25%

75%

66 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 apr. 2025, 23:55 UTC

Acțiuni populare

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 apr. 2025, 22:50 UTC

Principalele dinamici ale pieței

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 apr. 2025, 21:08 UTC

Câștiguri

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 apr. 2025, 21:00 UTC

Câștiguri

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 apr. 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 apr. 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2 apr. 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 apr. 2025, 23:44 UTC

Top știri

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 apr. 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 apr. 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 apr. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2 apr. 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 apr. 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 apr. 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 apr. 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 apr. 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 apr. 2025, 22:43 UTC

Top știri
Achiziții, Fuziuni, Preluări

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 apr. 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 apr. 2025, 21:48 UTC

Top știri

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 apr. 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 apr. 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 apr. 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 apr. 2025, 21:04 UTC

Top știri

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 apr. 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 apr. 2025, 20:53 UTC

Câștiguri

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 apr. 2025, 20:52 UTC

Câștiguri

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparație

Modificare preț

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

43.34% sus

Prognoză pe 12 luni

Medie 73.75 EUR  43.34%

Maxim 82 EUR

Minim 65.5 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

51.4 / 52.35Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Neutral Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

66 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.